Tighter BP control may be advisable for elderly

GSK gets EU approval for 1st gene therapy in children

NEW YORK, May 30, (RTRS): A new study might help doctors answer the controversial question of what’s the healthiest blood pressure for older adults.

In adults above age 75 who could walk without assistance, keeping the top blood pressure number below 120 millimeters of mercury (mmHg) led to significantly lower rates of cardiovascular events and deaths from any cause, the study found.

There had been some fear that bringing the top number — called the systolic pressure — down below 120 mmHg might actually be risky for older individuals. If their blood pressure were too low, they’d be vulnerable to falls and other problems.

We can reassure patients, especially from this study, that lowering blood pressure is safe. There were no more serious adverse events or falls among people on intensive blood pressure control versus those on standard control, Dr Jeff D. Williamson, of the Sticht Center on Aging at Wake Forest School of Medicine in Winston-Salem, North Carolina, told Reuters Health in a phone interview.

Rigorous

This is really important news because there’s been a lot of news (about studies) using administrative databases and self report that has indicated to older people that it’s dangerous to treat blood pressure; you might fall more. This is the most rigorous scientific study to ever look at that and it shows that that’s really not true. Thats actually been found the case in other blood pressure studies but not to this level of detail, Williamson said.

Williamson and colleagues analyzed data on 2,636 participants with high blood pressure in the Systolic Blood Pressure Intervention Trial who were 75 or older.

The systolic blood pressure reflects the pressure in the vessels as the heart contracts to push blood out to the body.

Overall, 1,317 patients had been randomly assigned to have their systolic blood pressure brought down with medication until it was 120 mmHg. In another 1,319, doctors tried to achieve a target systolic blood pressure of 140 mmHg.

As reported in the Journal of the American Medical Association, over the next three years, on average, the group with the lower blood pressure target had significantly fewer cardiovascular events and fewer deaths.

The rate of serious adverse events did not differ between the treatment groups.

The study had a fairly representative sample of older people who would typically come to their doctor’s office, not living in a nursing home or assisted living, Williamson said. The results apply to a broad spectrum of people, and it only required one additional medication on average to achieve this result. It’s relatively practical, 90 percent of the medications used were generic, he said.

There’s so much hypertension in older people we almost begin to see it as normal. It can lull us to think this is not practical, he added. The study shows that a lot of people are eligible to have better blood pressure.

This study very carefully measured blood pressure and did it three times in the office without the doctor present to avoid white coat hypertension, but also to avoid what often happens in a doctor’s office: the patient runs in from the parking lot flustered to take the blood pressure and it might be high, Williamson explained.

Accurate

Health systems will need to make more accommodation for more accurate assessment of patients, especially in the area of blood pressure. It’s very important now to begin to look at how electronic medical records and valuebased care models can incentivize the health care system to implement this, he concluded.

In an editorial, Dr Aram V. Chobanian of Boston University School of Medicine wrote that bringing systolic blood pressure down below 130 mmHg in older patients “may be challenging for clinicians, because doing so could require use of additional medications, more careful monitoring, and more frequent clinic visits.”

“Nevertheless”, he concluded, “the important results reported by Williamson et al in this issue of JAMA cannot be discounted, and unless unexpected adverse effects are observed on further examination of the trial data, then major changes in treatment goals for patients 75 years or older with hypertension will be warranted.”

Also:

LONDON: The world’s first life-saving gene therapy for children, developed by GlaxoSmithKline and Italian scientists, was approved for sale in Europe on Friday, in a step forward for the pioneering technology to fix faulty genes.

Called Strimvelis, it is designed for a tiny number of children with ADA Severe Combined Immune Deficiency (ADA-SCID). SCID is sometimes known as bubble baby disease, since those born with it have immune systems so weak they must live in germfree environments. Strimvelis is the second gene therapy to be approved in Europe, after UniQure’s Glybera, which treats a rare adult blood disorder.

Glybera made history in 2014 as the first drug to carry a $1 million price tag. GSK has not so far revealed how much its product will cost but a source close to the company said last month it would be very significantly less than $1 million.

The EU approval for GSK’s treatment had been expected, following a positive opinion from the European Medicines Agency last month.